Tanvi Sood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tanvi Sood has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kshitija Mittal
Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India
7 shared publications - Ravneet Kaur
Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India
7 shared publications - Paramjit Kaur
Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India
6 shared publications - Gagandeep Kaur
Department of Transfusion Medicine, Government Medical College and Hospital, Chandigarh, India
2 shared publications Kshitija Mittal
Chandigarh, India
2 shared publications- Rakesh Kumar
Department of Transfusion Medicine, Government Medical College and Hospital, Sector 32, Chandigarh, India
2 shared publications
Latest Publications
- 24 February 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 460-468
Effect of Age of Transfused Red Blood Cell Units on Clinical Outcomes in Critically Ill Patients
Anemia in critically ill patients requires red cell transfusions to increase oxygen delivery and prevent deleterious outcomes. The primary objective of the present study was to determine the effect of storage age of transfused red cells on 30-day mortality in critically ill patients, with secondary objectives of determining the effect on length of stay, organ failure, and adverse transfusion reactions. This prospective study was conducted on patients admitted to the intensive care unit after obtaining approval from institutional ethics committee. Patients were randomized to transfusion with packed red blood cells (PRBC) with age of collection either ≤ 14 days (Group 1) or > 14 days (Group 2). APACHE II scores were calculated at admission. Patients were followed up for primary outcome of 30-day mortality, and secondary outcomes including length of stay, infections, organ dysfunction, and adverse transfusion reactions. The 30-day mortality was 20% in Group 1 and 28% in Group 2 (p = 0.508). The mean storage duration of PRBC in Group 1 versus Group 2 was 8.48 days versus 21.43 days (p < 0.001). There was no significant difference in total number of PRBC transfusions, donor exposures, hemoglobin and hematocrit increment, adverse transfusion reactions, length of stay and organ dysfunction scores between the two groups. Transfusion of packed red cells of less than 14 days showed no benefit over red cells stored more than 14 days in terms of 30-day mortality, length of stay and infections in critically ill patients, however studies with larger sample size and longer follow up are recommended.
- 24 February 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (3) , 460-468
Effect of Age of Transfused Red Blood Cell Units on Clinical Outcomes in Critically Ill Patients
Anemia in critically ill patients requires red cell transfusions to increase oxygen delivery and prevent deleterious outcomes. The primary objective of the present study was to determine the effect of storage age of transfused red cells on 30-day mortality in critically ill patients, with secondary objectives of determining the effect on length of stay, organ failure, and adverse transfusion reactions. This prospective study was conducted on patients admitted to the intensive care unit after obtaining approval from institutional ethics committee. Patients were randomized to transfusion with packed red blood cells (PRBC) with age of collection either ≤ 14 days (Group 1) or > 14 days (Group 2). APACHE II scores were calculated at admission. Patients were followed up for primary outcome of 30-day mortality, and secondary outcomes including length of stay, infections, organ dysfunction, and adverse transfusion reactions. The 30-day mortality was 20% in Group 1 and 28% in Group 2 (p = 0.508). The mean storage duration of PRBC in Group 1 versus Group 2 was 8.48 days versus 21.43 days (p < 0.001). There was no significant difference in total number of PRBC transfusions, donor exposures, hemoglobin and hematocrit increment, adverse transfusion reactions, length of stay and organ dysfunction scores between the two groups. Transfusion of packed red cells of less than 14 days showed no benefit over red cells stored more than 14 days in terms of 30-day mortality, length of stay and infections in critically ill patients, however studies with larger sample size and longer follow up are recommended.
- 6 September 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 62 (2) , 103569
Exploring the unseen effect of COVID 19 pandemic on blood transfusion services in a tertiary care centre
- 6 September 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 62 (2) , 103569
Exploring the unseen effect of COVID 19 pandemic on blood transfusion services in a tertiary care centre
- 25 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (4) , 791-796
Efficacy of packed red blood cell transfusions based on weight versus formula in thalassemic children: An open‐label randomized control trial
Background: Protocols for transfusion therapy in transfusion‐dependent thalassemia (TDT) children differ among various medical centers. In India, most centers consider only the patient's weight while calculating the volume of packed red blood cells (PRBCs) to be transfused. This study aimed to compare the efficacy of PRBC transfusions of different volumes calculated either by weight or by a formula using weight and pretransfusion hemoglobin of patient and hematocrit of PRBC.Study Design and Methods: Sixty TDT patients in the age group of 3–9 years were enrolled and randomly allocated to two groups. Group A received PRBC transfusion volume based on the patient's weight, and Group B received PRBC volume calculated using a formula for 6 months.Results: Average pretransfusion hemoglobin in Group A and Group B (9 ± 0.4 vs. 8.9 ± 0.4 g/dl) was not significantly different (p = .353). Although the average number of visits in 6 months was less for Group A compared to Group B (7 ± 1 vs. 8 ± 1; p = .001); the average volume transfused per visit was more (351 ± 78 vs. 287 ± 68 ml; p = .003). The calculated average annual pure red cell requirement of the patients was 178 ml/kg/year for Group A and 154 ml/kg/year for Group B (p = .000). Total donor exposures were significantly lower in Group B than Group A (11 ± 3 vs. 14 ± 3; p = .006).Conclusion: The number of donor exposures and annual pure red cell requirement was significantly lower in the formula‐based group. Transfusions based on formula are recommended in TDT patients.
- 25 February 2022
- Published by Wiley in Transfusion
- Vol. 62 (4) , 791-796
Efficacy of packed red blood cell transfusions based on weight versus formula in thalassemic children: An open‐label randomized control trial
Background: Protocols for transfusion therapy in transfusion‐dependent thalassemia (TDT) children differ among various medical centers. In India, most centers consider only the patient's weight while calculating the volume of packed red blood cells (PRBCs) to be transfused. This study aimed to compare the efficacy of PRBC transfusions of different volumes calculated either by weight or by a formula using weight and pretransfusion hemoglobin of patient and hematocrit of PRBC.Study Design and Methods: Sixty TDT patients in the age group of 3–9 years were enrolled and randomly allocated to two groups. Group A received PRBC transfusion volume based on the patient's weight, and Group B received PRBC volume calculated using a formula for 6 months.Results: Average pretransfusion hemoglobin in Group A and Group B (9 ± 0.4 vs. 8.9 ± 0.4 g/dl) was not significantly different (p = .353). Although the average number of visits in 6 months was less for Group A compared to Group B (7 ± 1 vs. 8 ± 1; p = .001); the average volume transfused per visit was more (351 ± 78 vs. 287 ± 68 ml; p = .003). The calculated average annual pure red cell requirement of the patients was 178 ml/kg/year for Group A and 154 ml/kg/year for Group B (p = .000). Total donor exposures were significantly lower in Group B than Group A (11 ± 3 vs. 14 ± 3; p = .006).Conclusion: The number of donor exposures and annual pure red cell requirement was significantly lower in the formula‐based group. Transfusions based on formula are recommended in TDT patients.
- 15 December 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , xi5
Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors
There exists a need for a prognostic marker apart from PDL1 expression for patients being treated with immunotherapy. Neutrophil lymphocyte ratio (NLR) has been shown to correlate with outcomes in certain malignancies treated with immune checkpoint inhibitors (ICI). A retrospective analysis was carried out of a total of 70 patients who received ICI for metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC) from 2016-2019. Peripheral blood NLR of 5 at baseline was used as cut off to divide patients into two groups. Objective response rate (ORR) and overall survival (OS) were calculated in the two groups. 37 patients of mRCC and 33 patients of mNSCLC were treated with ICI. Among the 37 with mRCC , 24 patients (64.9%) had a NLR less than 5. Those with NLR5 group (p = 0.01).There was also a marked significant difference in the survival between the two groups with median OS not reached in NLR5 group( HR = 0.12 , 95% CI : 0.04-0.40, p = 0.00). Three patients with NLR< 5 have a ongoing complete response of 40, 38, and 30 months respectively. Among the 33 patients of mNSCLC, 19 patients (57.5%) had NLR of < 5 . Those with NLR5 . Those with NLR5 (HR = 0.59). Patients with low NLR had a significantly better response rate and overall survival. In a resource and cost constraint setting, a simple inexpensive test such as NLR would not only be prognostic, but can help in choosing treatment strategies in scenarios where PDL-1 expression does not carry any implication such as in 2nd line mRCC and 2nd line mNSCLC. Also with the advent of combination regimens in 1st line setting (chemo+ ICI in mNSCLC and oral TKI+ICI in mRCC), large scale studies need to be done on whether those with low NLR can benefit with only single agent ICI which would have an impact in not only lowering the cost burden in a developing country such as India but also maintain a better quality of life. Nitin Yashas Murthy. Has not received any funding. All authors have declared no conflicts of interest.
- 15 December 2019
- Published by Elsevier in Annals of Oncology
- Vol. 30 (Supplement) , xi5
Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors
There exists a need for a prognostic marker apart from PDL1 expression for patients being treated with immunotherapy. Neutrophil lymphocyte ratio (NLR) has been shown to correlate with outcomes in certain malignancies treated with immune checkpoint inhibitors (ICI). A retrospective analysis was carried out of a total of 70 patients who received ICI for metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC) from 2016-2019. Peripheral blood NLR of 5 at baseline was used as cut off to divide patients into two groups. Objective response rate (ORR) and overall survival (OS) were calculated in the two groups. 37 patients of mRCC and 33 patients of mNSCLC were treated with ICI. Among the 37 with mRCC , 24 patients (64.9%) had a NLR less than 5. Those with NLR5 group (p = 0.01).There was also a marked significant difference in the survival between the two groups with median OS not reached in NLR5 group( HR = 0.12 , 95% CI : 0.04-0.40, p = 0.00). Three patients with NLR< 5 have a ongoing complete response of 40, 38, and 30 months respectively. Among the 33 patients of mNSCLC, 19 patients (57.5%) had NLR of < 5 . Those with NLR5 . Those with NLR5 (HR = 0.59). Patients with low NLR had a significantly better response rate and overall survival. In a resource and cost constraint setting, a simple inexpensive test such as NLR would not only be prognostic, but can help in choosing treatment strategies in scenarios where PDL-1 expression does not carry any implication such as in 2nd line mRCC and 2nd line mNSCLC. Also with the advent of combination regimens in 1st line setting (chemo+ ICI in mNSCLC and oral TKI+ICI in mRCC), large scale studies need to be done on whether those with low NLR can benefit with only single agent ICI which would have an impact in not only lowering the cost burden in a developing country such as India but also maintain a better quality of life. Nitin Yashas Murthy. Has not received any funding. All authors have declared no conflicts of interest.
- 22 October 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (2) , 298-299
Clinically Significant IgM Anti-Cw: A Rare Report
- 22 October 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (2) , 298-299
Clinically Significant IgM Anti-Cw: A Rare Report
- 20 June 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 32 (4) , 497-499
Clinical Significance of Rare Maternal Anti Jka Antibody
We hereby report a rare case of HDFN because of antibody to Kidd (Jk) blood group system—anti Jka. An EDTA sample of a baby along with mother’s sample was received in the Department for Direct Antiglobulin Test (DAT) alongwith blood requisition for double volume exchange transfusion. On blood grouping, baby’s and mother’s blood group was found to be B Rh D positive. DAT with polyspecific anti human globulin (AHG) was positive. Screening of mother’s serum for irregular antibodies showed anti-Jka antibody. AHG phase titers using tube technique were 1:64. Mother was found to be Jka antigen negative; father and neonate were found to be Jka antigenpositive. Antibody was observed to be of IgG type on Dithiothreitol treatment. Baby had total serum bilirubin of 20.5 mg/dl on day 3 of life and phototherapy was started. Exchange transfusion was not required in the baby. The present case emphasises the significance of minor blood group antigens other than Rh blood group system as a cause of HDFN. Although HDFN due to Jk antibodies is rare, however, the clinician must be aware of the occurrence of these antibodies as they can lead to severe HDFN and persistent anemia in the infant.
- 20 June 2016
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 32 (4) , 497-499
Clinical Significance of Rare Maternal Anti Jka Antibody
We hereby report a rare case of HDFN because of antibody to Kidd (Jk) blood group system—anti Jka. An EDTA sample of a baby along with mother’s sample was received in the Department for Direct Antiglobulin Test (DAT) alongwith blood requisition for double volume exchange transfusion. On blood grouping, baby’s and mother’s blood group was found to be B Rh D positive. DAT with polyspecific anti human globulin (AHG) was positive. Screening of mother’s serum for irregular antibodies showed anti-Jka antibody. AHG phase titers using tube technique were 1:64. Mother was found to be Jka antigen negative; father and neonate were found to be Jka antigenpositive. Antibody was observed to be of IgG type on Dithiothreitol treatment. Baby had total serum bilirubin of 20.5 mg/dl on day 3 of life and phototherapy was started. Exchange transfusion was not required in the baby. The present case emphasises the significance of minor blood group antigens other than Rh blood group system as a cause of HDFN. Although HDFN due to Jk antibodies is rare, however, the clinician must be aware of the occurrence of these antibodies as they can lead to severe HDFN and persistent anemia in the infant.
- 1 September 2014
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 8 (5) , 528
Turbid blood unit: A second look
- 1 September 2014
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 8 (5) , 528
Turbid blood unit: A second look
- 1 September 2014
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 53 (3) , 97-98
Transfusion support to thalassemic patients in a resource poor setting: Still a long way to go
- 1 September 2014
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 53 (3) , 97-98
Transfusion support to thalassemic patients in a resource poor setting: Still a long way to go
- 1 April 2014
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 50 (2) , 239-241
DAT positivity in blood donors: A perplexing scenario
- 1 April 2014
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 50 (2) , 239-241
DAT positivity in blood donors: A perplexing scenario
- 1 December 2013
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 49 (3) , 613-614
Tetany by transfusion of small volume of blood: A rare case report
- 1 December 2013
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 49 (3) , 613-614
Tetany by transfusion of small volume of blood: A rare case report